The report covers forecast and analysis for the radiopharmaceutical market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Million) and volume. The study includes drivers and restraints for the radiopharmaceutical along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the radiopharmaceutical market on a global level.
In order to give the users of this report a comprehensive view on the radiopharmaceutical market, we have included a detailed segmentation of radiopharmaceutical. To understand the competitive landscape in the market, an analysis of Porters Five Forces model for the radiopharmaceutical market has also been included. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view on the radiopharmaceutical market by segmenting the market based on type and application. Diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals are the type segment of Radiopharmaceuticals market. Cardiology, neurology, oncology and other are the key application segment of radiopharmaceutical market. All the application segments have been analyzed based on present and future trends and the market is estimated from 2015 to 2021.
Some of the major players in the radiopharmaceuticals market include Cardinal Health, Inc., GE Healthcare, Bracco Imaging S.p.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc., Advanced Accelerator Applications S.A., Bayer Healthcare, Lantheus Medical Imaging, Inc., IBA Molecular Imaging, Mallinckrodt plc, Jubilant Pharma, and Siemens Healthcare.
The report segments the global radiopharmaceuticals market as:
Radiopharmaceuticals Market: Type Segment Analysis
Radiopharmaceuticals Market: Application Segment Analysis
Radiopharmaceuticals Market: Regional Segment Analysis
